ALRN
Companies
NASDAQ
Aileron Therapeutics, Inc.
Health Care
$2.01
-$0.31 (-13.36%)
Price Chart
Overview
About ALRN
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
Market Cap
$70.0M
Volume
65.5K
Avg. Volume
111.4K
P/E Ratio
-1.1853932
Dividend Yield
0.00%
Employees
21.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.80
Moderate Correlation
Volatility
High (1.00)
Relative to market
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALRN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$70.0M
Volume65.5K
P/E Ratio-1.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
November 15, 2024Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025